Full profile
| Also known as | CocoaVia, Epicatechin |
|---|---|
| Best for | Acute cerebral blood flow support · Acute attention support |
| Evidence grade | Grade B — Moderate — several human trials, some mixed results |
| Studied dose range | ~500 mg cocoa flavanols/day (roughly 80 mg epicatechin). |
| Time to effect | Acute — cerebral blood flow and attention effects measured within hours of a single dose. |
| Best form | CocoaVia or an equivalent de-theobrominated, low-theobromine cocoa flavanol extract, to keep the product stimulant-free. |
Evidence, honestly graded
Qualified B. Acute cerebral-blood-flow RCTs (Scientific Reports, 2020) found a single dose improved blood flow and attention measures. But the large chronic COSMOS trial (2023, doi:10.1002/alz.12767) — a multi-year trial in older adults — was null on its primary global-cognition endpoint. We state that plainly: the acute signal is real, the chronic global-cognition claim is not supported by the best available trial. Funding transparency: much cocoa-flavanol research (and the CocoaVia-branded material) is tied to Mars; notably COSMOS itself was NIH-funded with Mars supplying the study product, so the chronic null is not a sponsor-captured result — but the acute-claim base still warrants the same sponsor caveat carried on other branded entries.
See the full grading rubric — study type, replication, population match, and dose adequacy — in The Evidence Standard.
Side effects
- Generally well tolerated
- Excellent overall safety profile
Interactions
- No material known interactions at studied doses
Stacks well with
What to look for on a label
- Specify a de-theobrominated or low-theobromine extract to keep the stimulant-free positioning honest — regular cocoa extract carries meaningful theobromine.
- Frame as acute blood-flow/attention support, not a chronic global-cognition benefit — the largest chronic trial (COSMOS) was null on that endpoint.
References
- Acute cocoa flavanol cerebral blood flow RCTs, Scientific Reports 2020. Single dose improved cerebral blood flow and attention measures in healthy adults versus placebo. PMID 33235219. Educational, not a product claim.
- COSMOS 2023 — chronic cocoa flavanol trial, null primary endpoint. Large, multi-year RCT in older adults; null on its primary global-cognition endpoint. doi:10.1002/alz.12767. Stated plainly as the honest limit on the chronic claim.
Grades and studied doses are our conservative reading of the human research, shown for education. They are not product claims, and a studied dose is not a recommended dose.
Revision history
Every change to this ingredient's evidence status, dated and explained. The full cross-library log lives at Evidence Updates.
- 2026-07-07New profile
Initial profile published at Grade B (qualified): acute cerebral-blood-flow and attention effects are demonstrated, while the large chronic trial (COSMOS) was null on its primary global-cognition endpoint.
See how Cocoa Flavanols compares on grade, dose, and goal in the Evidence Explorer.
